×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APRE – aprea therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APRE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
08:14 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/11
08:33 am
apre
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]
Low
Report
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward [Yahoo! Finance]
12/11
08:30 am
apre
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Medium
Report
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
11/18
08:07 am
apre
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
High
Report
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/13
11:16 am
apre
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Low
Report
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
11/10
09:02 am
apre
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/7
10:32 am
apre
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
08:00 am
apre
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:56 pm
apre
Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC
Low
Report
Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC
11/8
04:39 pm
apre
Form 8-K Aprea Therapeutics, Inc. For: Nov 08
Low
Report
Form 8-K Aprea Therapeutics, Inc. For: Nov 08
11/8
04:33 pm
apre
Form 424B5 Aprea Therapeutics, Inc.
Low
Report
Form 424B5 Aprea Therapeutics, Inc.
11/7
08:38 am
apre
Form 8-K Aprea Therapeutics, Inc. For: Nov 07
Low
Report
Form 8-K Aprea Therapeutics, Inc. For: Nov 07
11/7
08:36 am
apre
Form 10-Q Aprea Therapeutics, Inc. For: Sep 30
Low
Report
Form 10-Q Aprea Therapeutics, Inc. For: Sep 30
10/25
05:42 pm
apre
Form 4 Aprea Therapeutics, Inc. For: Oct 18 Filed by: Duey Marc
Medium
Report
Form 4 Aprea Therapeutics, Inc. For: Oct 18 Filed by: Duey Marc
10/24
08:30 am
apre
Form 4 Aprea Therapeutics, Inc. For: Oct 23 Filed by: Gilad Oren
Neutral
Report
Form 4 Aprea Therapeutics, Inc. For: Oct 23 Filed by: Gilad Oren
10/23
09:01 am
apre
Form 8-K Aprea Therapeutics, Inc. For: Oct 23
Low
Report
Form 8-K Aprea Therapeutics, Inc. For: Oct 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/2
Form 3 Aprea Therapeutics, Inc. For: Oct 02 Filed by: Coiante Scott M
32.6%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%
12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%
3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%
4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%
10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%
10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%
1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%
10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%
11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%
TOP News Decliners
3/26
Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus -0.390 ActVsEst (0.250) - Miss
-11.5%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%
12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%
10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%
4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%
2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%
2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%
10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%
11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%
1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: